Weight Loss Medications: GLP-1 and Non-GLP-1 Options
Modern obesity medicine includes weekly injections, daily tablets, combination medicines and established short-term prescriptions. This guide organizes the major choices so patients can ask better questions during a medical evaluation.
What patients should know
Medication selection begins with diagnosis and risk assessment rather than popularity. Clinicians consider BMI, blood pressure, cardiovascular history, diabetes, sleep apnea, kidney or liver concerns, gastrointestinal disease, mental-health history, seizure risk, opioid therapy, pregnancy plans and other medicines.
Brand names and active ingredients matter. Wegovy and Ozempic contain semaglutide but have different approved uses. Zepbound and Mounjaro contain tirzepatide but likewise have different approved indications. Using a diabetes brand for weight loss is not the same as using the weight-management brand under its labeled indication.
Who may be evaluated
- People meeting labeled BMI and comorbidity criteria
- Patients seeking an alternative after intolerance or inadequate response
- People willing to combine medication with nutrition, movement and follow-up
- Patients whose medication list and medical history allow safe prescribing
Potential advantages
- Incretin options that affect appetite and fullness
- Non-GLP-1 choices when injections are undesirable or unsuitable
- Short-term options for carefully selected patients
- A maintenance plan that anticipates regain risk
At-a-glance comparison
| Class | Examples | Important distinction |
|---|---|---|
| GLP-1 | Wegovy, Saxenda | Semaglutide and liraglutide differ in schedule, efficacy and labeling |
| GIP/GLP-1 | Zepbound | Contains tirzepatide and should not be combined with other tirzepatide or GLP-1 products |
| Combination oral | Qsymia, Contrave | Each has unique contraindications and titration rules |
| Lipase inhibitor | Orlistat | GI effects and fat-soluble vitamin considerations |
| Sympathomimetic | Phentermine, diethylpropion, phendimetrazine | Controlled medicines requiring cardiovascular and interaction screening |
Safety and medical supervision
- Do not borrow, share or combine weight-loss prescriptions.
- Use the product-specific prescribing information; warnings differ by medication.
- Rapid dose escalation can increase adverse effects for medicines that require titration.
- Report severe or persistent symptoms promptly and seek emergency care when appropriate.
This summary cannot replace the current FDA-approved prescribing information or an individualized medical evaluation. Tell the clinician about every prescription, over-the-counter medicine, supplement, allergy, pregnancy plan and relevant medical condition.
How W8MD can help
Personalized evaluation
W8MD reviews weight history, prior attempts, conditions, medicines, contraindications, sleep, nutrition, goals, insurance and cost.
Follow-up and maintenance
Care may include response monitoring, adverse-effect management, dose planning, nutrition, lean-mass goals, sleep-apnea evaluation and long-term maintenance.
Brooklyn / NYC: 2632 East 21st Street, Suite L3, Brooklyn, NY 11235 · 718-946-5500
Northeast Philadelphia: 1718 Welsh Road, 2nd Floor, Suite C, Philadelphia, PA 19115 · 215-676-2334
Medical evaluation is required. Eligibility, prescription, availability, coverage, price, response and adverse effects vary.
Related W8MD resources
Prescription hub · GLP-1 comparison · Semaglutide · Tirzepatide · Phentermine · Insurance · Medical weight loss · W8MD.com medication guides · NYC medical weight loss · Philadelphia medical weight loss · Anti-obesity medication encyclopedia
Frequently asked questions
Are all weight loss medications GLP-1 drugs?
No. Qsymia, Contrave, orlistat, phentermine and other established prescriptions work through different mechanisms.
Can I switch medications?
Sometimes, but switching requires a prescriber-directed plan that considers washout, titration, adverse effects and overlapping ingredients.
How long is treatment needed?
Duration depends on the medication, response, safety, coverage and maintenance strategy. Some medicines are labeled for chronic treatment, while phentermine is labeled as a short-term adjunct.
Authoritative references
References are provided for education. Product labeling changes; clinicians and patients should consult the current FDA-approved label.
Request a W8MD callback
For appointments and time-sensitive questions, call Brooklyn at 718-946-5500 or Philadelphia at 215-676-2334. Do not submit urgent, confidential medical, insurance, financial or identifying information through this general form.
You must be logged in to post a comment.